Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Natera, Inc.
NTRA
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $39.6B
$276.43
▲ +0.06%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$131.81 - $279.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 71.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary cell-free DNA testing technology with established clinical validation
- Comprehensive product portfolio spanning prenatal, reproductive, oncology, and transplant diagnostics
- Extensive distribution network of 100+ laboratory partners enabling broad market access
- Strategic partnerships with BGI Genomics and Foundation Medicine for product development
- Cloud-based Constellation platform creating recurring revenue and customer lock-in
Bear Case
2 risks
- Above-average volatility (beta 1.5).
- Growth premium of 0.0x vs Life Sciences Tools peers. Reasonable for this growth rate.
Growth
Stable outlook
Expanding adoption of non-invasive prenatal testing (NIPT) as standard of care in obstetrics
Value
Growth premium of 0.0x vs Life Sciences Tools peers. Reasonable for this growth rate.
Momentum
Hot
+32.8% over 3m
Quality
Excellent
High-growth business (37% revenue growth, 65% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying NTRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of -$0.56 vs -$0.53 consensus (-5.7% surprise). Revenue of $696.6M vs $617.1M expected (+12.9%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-5.7%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+53%
+36%
+32%
+35%
+40%
+39%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$413.4M
$439.8M
$476.1M
$501.8M
$546.6M
$592.2M
$665.5M
$696.6M
Margins · last 8Q
Gross
64.8%
Operating
-13.4%
Profit
-12.2%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
$265.00
▼ -4.1% vs $276.43
Latest: Guggenheim · $290.00 · Jun 29, 2026
5 analysts covering